TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05929300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga program includes up to 4 weeks of pre-habilitation yoga and 8 weeks of post-surgery yoga. The yoga program includes basic yoga poses and breathing exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This consists of usual care patients. It is current practice for all patients to: 1) receive a handout that covers Kegel exercises; and, 2) instruction from a nurse who teaches the patient how to perform the exercises. There is no referral to a physical therapist unless progression indicates a need for it.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: This consists of usual care patients. It is current practice for all patients to: 1) receive a handout that covers Kegel exercises; and, 2) instruction from a nurse who teaches the patient how to perform the exercises. There is no referral to a physical therapist unless progression indicates a need for it.
Study: NCT05832008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Nudge
Description: EHR-based Prompts - an pended order and message that alerts a clinician if a patient is due for screening or diagnostic follow-up.
Study: NCT05572684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC410
Description: NC410 will be given intravenously (IV) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab 400mg will be given IV every 6 weeks.
Study: NCT05232253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cystoelastometer - Urodynamics Testing
Description: The non-invasive cystoelastometer device connects to the drainage end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device a pressure measurement is recorded and stored in the device along with the time and date. The remaining urine is then evacuated through the catheter and device and the cystoelastometer records the volume of urine evacuated. The measurement(s) of bladder pressure and volume as well as the time and date can later be transmitted wirelessly to a smart phone that contains an app for the device.
Study: NCT05700201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle / Healthy Behavior Intervention
Description: 12-session healthy lifestyle program focused on physical activity, nutrition, sleep, and stress management.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: Standard care (psychotherapy)
Study: NCT05069896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab Prefilled Syringe
Description: Administered SC by prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab Autoinjector
Description: Administered SC by autoinjector
Study: NCT05196672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality and eye mask
Description: Adults will receive a virtual reality program 30 min before bedtime and then be placed on an eye mask during their sleep for consecutive 2 nights of ICU stay.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality and eye mask
Description: Adults will receive a virtual reality program 30 min before bedtime and then be placed on an eye mask during their sleep for consecutive 2 nights of ICU stay.
Study: NCT06602765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tooth brushing, tooth paste containing 1450ppm fluoride
Description: brushing with fluoride toothpaste, dietary counselling for caries prevention and application of fissure sealant compound on first permanent t molars.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tooth brushing, tooth paste containing 1450ppm fluoride
Description: brushing with fluoride toothpaste, dietary counselling for caries prevention and application of fissure sealant compound on first permanent t molars.
Study: NCT05187156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation and Social Engagement
Description: brief, PCMHI-based psychotherapy using behavioral activation principles and focused attention on enhancement of social support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: treatment as usual in PCMHI includes participation in any other skills-based groups or brief individual psychotherapy and medication management offered in PCMHI
Study: NCT06602765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tooth brushing, tooth paste containing 1450ppm fluoride
Description: brushing with fluoride toothpaste, dietary counselling for caries prevention and application of fissure sealant compound on first permanent t molars.
Study: NCT06097494

Intervention type: OTHER
Intervention: No intervention
Description: Observational analysis of usual care only.

Intervention type: OTHER
Intervention: No intervention
Description: Observational analysis of usual care only.
Study: NCT06589908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELAX glasses
Description: Glasses which are a solution of audiovisual sedation by positiv distraction for hospital medical use
Study: NCT06604351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, Nab-Paclitaxel, and Carboplatin
Description: Cryoablation received at least 2 or more depending on the mass, with 2-3 cycles；Sintilimab 200 mg Q3W plus Nab-Paclitaxel 260mg / m2(Day 1) Q3W + carboplatin AUC 4.25 or 5 (Day 1) Q3W, 4 cycles，until 24 months
Study: NCT06569186

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cue-based feedings
Description: Speech therapists will use cue-based protocols to guide feeds
Study: NCT06601842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICP monitoring
Description: ICP monitoring
Study: NCT06260956

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consumption
Description: Subjects consume peanut and egg from 27 weeks of pregnancy through the first 4 months feeding breastmilk to their infant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Avoidance
Description: Subjects avoid eating peanut and egg from 27 weeks of pregnancy through the first 4 months feeding breastmilk to their infant.
Study: NCT04780932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10mg
Description: Macitentan 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
Study: NCT06707636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Black Women's Stress and Wellness (B-SWELL) arm
Description: The B-SWELL arm consists of 8-weekly sessions. Sessions last 90 minutes and focus on stress reduction, heart disease, and healthy lifestyle changes. The American Heart Association's Life's Essential 8 metrics are leveraged and culturally tailored in the B-SWELL materials. Participants will also receive personalized health coaching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Wellness (WE) arm
Description: This is an attention control group. Participants placed in his arm will receive 8-weekly sessions focused on the Life's Essential 8 metrics.
Study: NCT06735339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinic for Multimorbidity
Description: The patient is assigned a healthcare coordinator. A review of the patient's medication history and a medication review are conducted. A functional assessment is performed, along with relevant measurements, and the patient consults with a specialist physician. A multidisciplinary team (MDT) conference is held with selected specialists, depending on the patient's needs. This may include a cardiologist, endocrinologist, pulmonologist, gastroenterologist, rheumatologist, nephrologist, geriatrician, clinical pharmacologist, psychiatrist, pain nurse, physiotherapist, occupational therapist, and the patient's GP.~The handover of information to the GP is agreed upon at the time of referral and can be carried out in writing, through virtual MDT participation, or by telephone.~In agreement with the patient, the clinic may initiate follow-up actions, such as counseling on medication or disease management. Additionally, the clinic may facilitate cross-sectoral activities, such as therapy.
Study: NCT06735664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo ultrasound guided biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo optional bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound guided biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO
Study: NCT06734663

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Clinical outcomes of sutured versus sutureless conjunctival autograft in primary pterygium excision
Description: Studies have concluded that pterygium surgical excision is the main treatment for pterygium. Pterygium excision with superior graft is the procedure followed most commonly at present. This is achieved by many methods, with the result differing from one method to another. The most important difference is the incidence of recurrence(4)But Varioustechniques such as Bare Sclera, Rotational Conjunctival Flap, Limbal Conjunctival Autograft, Amniotic Membrane Graft, and Free Conjunctival Autograft are also used for the removal of pterygium(3 ,4)Of the various possible alternative approaches, conjunctival autograft is usually preferred. Diverse methods for grafting with sutures, glue or autologous serum from the recipient bed are in use (5,6). Many adjunctive therapies like mitomycin C, corticosteroids, thiotepa, interferon-alpha- 2b, beta irradiation, 5-FU are being used to decrease the risk of recurrence after surgical removal of pterygium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical outcomes of sutured versus sutureless conjunctival autograft in primary pterygium excision
Description: Studies have concluded that pterygium surgical excision is the main treatment for pterygium. Pterygium excision with superior graft is the procedure followed most commonly at present. This is achieved by many methods, with the result differing from one method to another. The most important difference is the incidence of recurrence(4)But Varioustechniques such as Bare Sclera, Rotational Conjunctival Flap, Limbal Conjunctival Autograft, Amniotic Membrane Graft, and Free Conjunctival Autograft are also used for the removal of pterygium(3 ,4)Of the various possible alternative approaches, conjunctival autograft is usually preferred. Diverse methods for grafting with sutures, glue or autologous serum from the recipient bed are in use (5,6). Many adjunctive therapies like mitomycin C, corticosteroids, thiotepa, interferon-alpha- 2b, beta irradiation, 5-FU are being used to decrease the risk of recurrence after surgical removal of pterygium.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: pterygium excision and conjuctival graft suturing
Description: pterygium is surgically removed, and a conjuctival graft is placed on bare sclera using sutures to surrounding conjuctiva.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pterygium excision and conjuctival graft placement by autologous blood
Description: pterygium is surgically removed and a conjuctival graft is placed on bare sclera on which the patient's blood remains. the graft is left without sutures, adhering only by autologous blood.
Study: NCT06077812

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RELAXaHEAD Smartphone App
Description: Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RELAXaHEAD Smartphone App
Description: Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Training
Description: Participants will receive in-person training in migraine self-management techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Training
Description: Participants will receive virtual training in migraine self-management techniques.
Study: NCT06593808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Weaning from the incubator to open coat at a weight greater than or equal to 1400 grams
Description: They will be dressed in a woolen hat and dress, wrapped in a blanket and placed in crib with preheated mattress.Vital signs will be monitored daily.Axillary temperature will be measured every 3 hours for the first 12 hours, if above or equal to 36.5°C it will be measured every 6 hours for the next 36 hours. If normothermia for 48 hours, the preheated mattress will be turned off and temperature monitoring will be continued every 3 hours for 24 hours.If greater than or equal to 36.5°C, thermal control will be continued every 8 hours for 48 hours, at the end of which time, if normothermic, care will be confirmed.If not it will be placed back in the crib with heated mattress.If temperature still below 36.5°C, an additional blanket will be placed and it will be rechecked after 2 hours.If it remains below 36.5°C, the infant will be placed under a radiant lamp and the temperature will be checked after 3 hours.If hypothermia persists, the infant will be transferred back to the incubator.
Study: NCT06595680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medialipide 20% perfusion
Description: Each patient will receive during a 4 hours hemodialysis session a perfusion of Medialipide 20% at a rate of 0,11 g/kg/h. Medialipide will be perfused using the venous line connected to the hemodialysis machine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medialipide 20% perfusion
Description: Each patient will receive during a 4 hours hemodialysis session a perfusion of Medialipide 20% at a rate of 0,11 g/kg/h. Medialipide will be perfused using the venous line connected to the hemodialysis machine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl 0,9%
Description: Each patient will receive during a 4 hours hemodialysis session a perfusion of NACL 0,9% with a volume corresponding to the one of Medialipide 20%. NaCl 0,9% will be perfused using the venous line connected to the hemodialysis machine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl 0,9%
Description: Each patient will receive during a 4 hours hemodialysis session a perfusion of NACL 0,9% with a volume corresponding to the one of Medialipide 20%. NaCl 0,9% will be perfused using the venous line connected to the hemodialysis machine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Serial biological sampling for the measurement of different blood concentrations : electrolytes, serum protein , albumin, renal function (urea, creatinine), hemoglobin, hematocrit, liver test, lipid test, ketone bodies, 6 uremic toxins (including IS and p-CS), sodium octanoate and decanoate.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Serial biological sampling for the measurement of different blood concentrations : electrolytes, serum protein , albumin, renal function (urea, creatinine), hemoglobin, hematocrit, liver test, lipid test, ketone bodies, 6 uremic toxins (including IS and p-CS), sodium octanoate and decanoate.
Study: NCT04757168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOGA TM probe
Description: Each subject will be his own witness since the linear local shortening (LLS) will be measured successively in all patients before, then after stimulation of the scar zone (comparison of LLS measured in sinus rhythm then during stimulation in the scar zone for each patient.~Each subject being his own witness and the two recordings being made a few minutes apart, during the same procedure.
Study: NCT04819542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bandage
Description: Bandage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No bandage
Description: No bandage
Study: NCT05895292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM Milled Methacrylate Complete Removable Dentures based on bone-support concept.
Description: The patients will receive complete removable dentures designed based on the bone-support concept and digitally manufactured using a milling machine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.
Description: The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machine
Study: NCT06492642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education for Chronic Low Back Pain
Description: Patient education on chronic low back pain (LBP), including:~Day 5: Basic LBP education, types of LBP, red flags; Day 8: LBP guideline recommendations re: imaging; Day 11: LBP guideline recommendations re: use of rehabilitation services, sitting and standing desks; Day 14: LBP guideline recommendations re:pharmacologic management; Day 17: LBP guideline recommendations re: injections and surgery.
Study: NCT05094362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinal Reflex Operant Down Conditioning
Description: This is a training intervention in which people with a spinal cord injury are trained to reduce the activity of a certain spinal reflex. By decreasing this reflex, individuals decrease hyperactivity in the reflex and can reduce spasticity.
Study: NCT06239896

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated Group ACP Session
Description: Group Facilitators will adhere to the standardized scripts and protocols to engage participants in ACP through group sessions. Participants will view the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video. Participants are provided with a workbook to follow along with the movies. They are also provide the PREPARE easy-to-read advance directive legal forms that they can fill out when they are ready. These forms include new PSH-specific content and a PSH-specific cover letter.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated one-on-one ACP visits
Description: Facilitator adheres to the scripts and protocols to engage participants in advance care planning through one-on-one ACP sessions. Participants will view the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video. Participants are provided with a workbook that they can use to follow along with the movies. They are also provide the PREPARE easy-to-read advance directive legal forms that they can fill out when they are ready. These forms include new PSH-specific content and a PSH-specific cover letter.
Study: NCT06320405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Given IV
Study: NCT04752475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Furosemide 20 mg pill taken daily for 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical-appearing placebo pill taken daily for 5 days
Study: NCT06143085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root surface debridement
Description: Periodontitis patients are treated non-surgically by supra- and subgingival debridement followed by root surface debridement for moderately deep periodontal pockets (4 to 6mm)
Study: NCT06493981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Treatment with eltrombopag in a dose of (50-150mg/d)
Study: NCT05061563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Elinzanetant given orally as single dose capsule and intravenous as single dose in Period 1. Elinzanetant given orally as single dose capsule in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Elinzanetant given orally as single dose capsule and intravenous as single dose in Period 1. Elinzanetant given orally as single dose capsule in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole given orally once daily for 5 days in Period 2.
Study: NCT05780411

Intervention type: OTHER
Intervention: questionnaire
Description: The symptom related checklist questionnaire, Quality of life questionnaire, Coping strategies questionnaire, Distress thermometer

Intervention type: OTHER
Intervention: questionnaire
Description: The symptom related checklist questionnaire, Quality of life questionnaire, Coping strategies questionnaire, Distress thermometer